Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,884.50-10.95
Stock Analysis, IPO, Mutual Funds, Bonds & More

Artemis Global Life Sciences Ltd.

AllNewsAnnouncementRecos

BSE LIVE

Change:

Volume:

Open:

Prv. Close:

Today:

Artemis Global Life Sciences Ltd.

52-Wk:

Artemis Global Life Sciences Ltd.

Bid:

()

Offer:

()

NSE LIVE

Change:

Volume:

Open:

Prv. Close:

Today:

Artemis Global Life Sciences Ltd.

52-Wk:

Artemis Global Life Sciences Ltd.

Bid:

()

Offer:

()

Artemis Global Life Sciences Compliance Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,...

| Announcement

In Accordance with Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing herewith copy of Certificate dated 11th October, 2019 duly signed by Company Secretary in Practice stating timely dispatch of transfer/split/consolidation etc. of shares received by the Company during the six months period from 1st April, 2019 to 30th September, 2019.

Artemis Global Life Sciences Statement Of Investor Complaints For The Quarter Ended September 2019

| Announcement

<table border=1><tr bgcolor=#d6d6d6><th class=TTRow-left> No.of Investor complaints pending at the beginning of the quarter </th><th class=TTRow> No.of Investor complaints received during the quarter</th><th class=TTRow> No.of Investor complaints disposed of during the quarter </th><th class=TTRow> No.of Investor complaints unresolved at the end of the quarter </th></tr><tr><td class=TTRow>0</td><td class=TTRow>0</td><td class=TTRow>0</td><td class=TTRow>0</td></tr></table><table border=1><tr><td > <span style=font-weight:bold>Name of the Signatory </span> </td><td> :- </td><td>ANUJ SOOD</td></tr><tr><td ><span style=font-weight:bold>Designation </span></td><td> :- </td><td>Company Secretary and Compliance Officer</td></tr></table>

Artemis Global Life Sciences Fixation Of Record Date - Regulation 30 And 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 20...

| Announcement

we wish to inform you that the Special Committee of the Board of Directors of the Company at its meeting held on 14th October, 2019 have fixed the Record Date for the purpose of the Composite Scheme as 25th October, 2019 for determining the eligibility of the shareholders of the Company to whom equity shares of AMSL will be issued in terms of the Composite Scheme.

Artemis Global Life Sciences Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

| Announcement

Artemis Global Life Sciences Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly <a href="https://www.bseindia.com/stock-share-price/meetings/voting-results/540616"> Click here</a>

Artemis Global Life Sciences Shareholder Meeting / Postal Ballot-Scrutinizers Report

| Announcement

With the reference to the captioned matter, please note that in the 9th Annual Genernal Meeting of the Company held on September 30, 2019, the members have passed the items (items 1 to 2) mentioned in the Notice. The detailed results (Annexure-1) and the report of Scrutinizer dated September, 30, 2019 are attached herewith.

Artemis Global Life Sciences Announcement under Regulation 30 (LODR)-Newspaper Publication

| Announcement

Pursuant to Regulation 34 and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015

Artemis Global Life Sciences Annual General Meeting Of The Members Of The Company

| Announcement

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015, now we wish to inform that the ninth Annual general meeting of the members of the Company will be held on Monday, 30th September, 2019.(Detail provided in the annexure attached herewith).

Artemis Global Life Sciences Outcome Of The Board Meeting Held On 14Th August, 2019

| Announcement

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Board of Directors of the Company in their meeting held on 14.08.2019 have inter alia, considered and approved the following: Approved the Unaudited Financial results (Standalone and Consolidated) for the quarter ended 30th June, 2019 as recommended by the Audit Committee. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of duly signed un-audited financial results (Standalone and Consolidated), along with the Limited Review report by statutory auditor of the Company thereon, are attached herewith.

Artemis Global Life Sciences Announcement under Regulation 30 (LODR)-Newspaper Publication

| Announcement

Pursuant to Regulation 29 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, August 14, 2019, at Gurgaon inter alia, to consider and approve the standalone and consolidated un-audited financial results of the Company for the quarter ended June 30, 2019.

Artemis Global Life Sciences Shareholding for the Period Ended June 30, 2019

| Announcement

Artemis Global Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly <a href="http://www.bseindia.com/corporates/shpSecurities.aspx?scripcd=540616&qtrid=102.00">Click here</a>

Artemis Global Life Sciences Closure of Trading Window

| Announcement

Notice of Closure of Trading window

Artemis Global Life Sciences Format of Initial Disclosure to be made by an entity identified as a Large Corporate

| Announcement

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Compay</td><td>Artemis Global Life Sciences Ltd</td></tr> <tr><td>2</td><td>CIN</td><td>U85191DL2011PLC216530</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Anuj Sood <br/> Designation: Company Secretary <br/> EmailId: csanujsood@gmail.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Aashta Kalra <br/> Designation: CFO <br/> EmailId: Aastha-hans@yahoo.com</div> </div> <div> <br/> Date: 23/05/2019<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

Artemis Global Life Sciences Reg.24(A)-Annual Secretarial Compliance

| Announcement

<b>Annual Secretarial Compliance Report</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Period for which the report has been issued </td><td>31/03/2019</td></tr> <tr><td>2</td><td>Date of Report</td><td>30/04/2019</td></tr> <tr><td>3</td> <td>Name of the Certifying Firm </td> <td>RSMV & Co.</td></tr> <tr><td>4</td><td> Name of the Certifying Individual </td><td>Manoj Sharma</td></tr> <tr><td>5</td><td>Membership Type</td><td>FCS</td></tr> <tr><td>6</td><td> Membership Number </td><td>7516</td></tr> <tr><td>7</td><td> CP No. </td><td>11571</td></tr> <tr><td>8</td><td> Whether any observations/qualification reported by the Secretarial Auditor ? </td><td>NO</td></tr> </table> <br/><br/>

Artemis Global Life Sciences Result Of Board Meeting Dated 08.05.2019

| Announcement

Result of Board Meeting dated 08.05.2019

Artemis Global Life Sciences Pursuant To Reg. 7(3) Of SEBI (LODR) Regulation 2015

| Announcement

This is to certify that all the activities in relation to physical and electronic share transfer facility maintained by M/s Alankit Assignments Ltd. , Registered with SEBI, the RTA of Artemis Global life sciences Ltd.

Artemis Global Life Sciences Shareholding for the Period Ended March 31, 2019

| Announcement

Artemis Global Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly <a href="http://www.bseindia.com/corporates/shpSecurities.aspx?scripcd=540616&qtrid=101.00">Click here</a>

Artemis Global Life Sciences Closure of Trading Window

| Announcement

Artemis Global Life Sciences Results For The Quarter Ended 31St December, 2018

| Announcement

Sub: Outcome of the Board Meeting held on 04th February, 2019 Dear Sir/ Madam, In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that Board of Directors of the Company in their meeting held on 04.02.2019 have inter alia, considered and approved the un-audited financial results (standalone & consolidated) for the quarter ended 31st December, 2018 as recommended by Audit Committee. Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, a copy of duly signed un-audited financial results (standalone & consolidated), along with the Limited Review report by statutory auditor of the Company thereon is enclosed. The Board Meeting commenced at 01:45 p.m. and concluded at 02:25 p.m. Please take the above information on your records.

Artemis Global Life Sciences Results Of The National Company Law Tribunal (NCLT) Convened Meeting Held On 27Th January, 2019

| Announcement

Ref: Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 108 of the Companies Act, 2013 and Rule 20(4) of the Companies (Management and Administration) Rules, 2014 Dear Sir/ Madam, With the reference to the captioned matter, we wish to inform you that in accordance with the order dated 19th December, 2018 of the National Company Law Tribunal Bench at New Delhi, meeting of the equity shareholders of the Company and Secured Creditors & Unsecured Creditors of Artemis Medicare Services Limited (Amalgamated Company No. 2) was convened on Sunday, 27th January, 2019 for approving the composite scheme of amalgamation between Artemis Global Life Sciences Limited, Artemis Health Sciences Limited, Athena Eduspark Limited and Artemis Medicare Services Limited and their respective shareholders and creditors (Composite Scheme). The Equity Shareholders of the Company have duly approved the Composite Scheme with requisite majority, based on Scrutinizer report by way of remote evoting and polling paper. Details of the voting results of the meeting of the Equity Shareholders of the Company along with the copy of the Scrutinizer report are annexed herewith for your reference. Results of evoting along with the Scrutinizers Report are also available on the Companys website: www.aglsl.in. Further, in respect of Artemis Medicare Services Limited: (i) the Unsecured Creditors of Artemis Medicare Services Limited present and voted, have approved the Composite Scheme unanimously in favour of the Composite Scheme. (ii) the Secured Creditors of Artemis Medicare Services Limited present and voted, have approved the Composite Scheme unanimously voted in favour of the Composite Scheme. Submitted for your information and records

Artemis Global Life Sciences Shareholding for the Period Ended December 31, 2018

| Announcement

Artemis Global Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly <a href="http://www.bseindia.com/corporates/shpSecurities.aspx?scripcd=540616&qtrid=100.00">Click here</a>

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service